Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β
Polakit Teekakirikul, … , Christine E. Seidman, Jonathan G. Seidman
Polakit Teekakirikul, … , Christine E. Seidman, Jonathan G. Seidman
Published September 1, 2010
Citation Information: J Clin Invest. 2010;120(10):3520-3529. https://doi.org/10.1172/JCI42028.
View: Text | PDF
Research Article Cardiology Article has an altmetric score of 15

Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β

  • Text
  • PDF
Abstract

Mutations in sarcomere protein genes can cause hypertrophic cardiomyopathy (HCM), a disorder characterized by myocyte enlargement, fibrosis, and impaired ventricular relaxation. Here, we demonstrate that sarcomere protein gene mutations activate proliferative and profibrotic signals in non-myocyte cells to produce pathologic remodeling in HCM. Gene expression analyses of non-myocyte cells isolated from HCM mouse hearts showed increased levels of RNAs encoding cell-cycle proteins, Tgf-β, periostin, and other profibrotic proteins. Markedly increased BrdU labeling, Ki67 antigen expression, and periostin immunohistochemistry in the fibrotic regions of HCM hearts confirmed the transcriptional profiling data. Genetic ablation of periostin in HCM mice reduced but did not extinguish non-myocyte proliferation and fibrosis. In contrast, administration of Tgf-β–neutralizing antibodies abrogated non-myocyte proliferation and fibrosis. Chronic administration of the angiotensin II type 1 receptor antagonist losartan to mutation-positive, hypertrophy-negative (prehypertrophic) mice prevented the emergence of hypertrophy, non-myocyte proliferation, and fibrosis. Losartan treatment did not reverse pathologic remodeling of established HCM but did reduce non-myocyte proliferation. These data define non-myocyte activation of Tgf-β signaling as a pivotal mechanism for increased fibrosis in HCM and a potentially important factor contributing to diastolic dysfunction and heart failure. Preemptive pharmacologic inhibition of Tgf-β signals warrants study in human patients with sarcomere gene mutations.

Authors

Polakit Teekakirikul, Seda Eminaga, Okan Toka, Ronny Alcalai, Libin Wang, Hiroko Wakimoto, Matthew Nayor, Tetsuo Konno, Joshua M. Gorham, Cordula M. Wolf, Jae B. Kim, Joachim P. Schmitt, Jefferey D. Molkentin, Russell A. Norris, Andrew M. Tager, Stanley R. Hoffman, Roger R. Markwald, Christine E. Seidman, Jonathan G. Seidman

×

Figure 1

Hypertrophic α-MHC719/+ mice have cardiac hypertrophy, increased myocardial fibrosis, and non-myocyte cell proliferation.

Options: View larger image (or click on image) Download as PowerPoint
Hypertrophic α-MHC719/+ mice have cardiac hypertrophy, increased myocard...
(A) Masson trichrome–stained sections from prehypertrophic (Pre-) and hypertrophic (Hyp-) α-MHC719/+csa hearts revealed increased fibrosis (blue) in comparison with WTcsa hearts. Scale bar: 1 mm. (B) Light microscopy shows increased BrdU incorporation in sections from α-MHC719/+csa hearts (top panel, original magnification, ×50). Confocal immunofluorescence after WGA (green), DAPI (blue) stains, and BrdU antibodies revealed proliferating non-myocyte cells (magenta nuclei, arrowheads) in regions with increased fibrosis (bottom panel, original magnification, ×400). There was minor nonspecific antibody staining (*) outside the nuclei. In comparison with WTcsa heart sections, note that α-MHC719/+csa hearts have disorganized myocardial architecture. Scale bar: 75 μm. (C) Confocal immunofluorescence shows expression of α-smooth muscle actin and fibroblast-specific protein 1 (Fsp1/S100a4), detected using a FITC-conjugated α-smooth muscle actin mouse antibody (green) and S100a4 antibody (red), respectively. Note that FITC-conjugated α-smooth muscle actin labeled only vascular beds in WTcsa and hypertrophic α-MHC719/+csa hearts. Scale bar: 75 μm.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 4 patents
Referenced in 2 clinical guideline sources
278 readers on Mendeley
See more details